Parkinson’s Disease Treatment Market Size, Share, Companies & Trends Analysis Report by Medication Analysis ( Dopamine Precursor, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO(monoamine oxidase) Inhibitors, Others (anticholinergics, antihistaminics, etc.)) By Medical Devices Analysis ( Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices, Others), By End User Analysis( Hospitals, Clinics, Homecare setting, Others) Based On Region And Segment Forecasts, 2022 - 2028

  • Report ID: BMRC 62 | Number of pages: 200 | Published Date: Feb 2022

    Published | Category: Chemical And Materials | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Parkinson’s Disease Treatment Market Size, Share, Companies & Trends Analysis Report by Medication Analysis ( Dopamine Precursor, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO(monoamine oxidase) Inhibitors, Others (anticholinergics, antihistaminics, etc.)) By Medical Devices Analysis ( Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices, Others), By End User Analysis( Hospitals, Clinics, Homecare setting, Others) Based On Region And Segment Forecasts, 2022 - 2028 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

The Global Parkinson’s Disease Treatment Market is valued at USD 6352.7 Million in 2021 and is expected to reach USD 9678.9 Million by 2028 with a CAGR of 6.2% over the forecast period.

Scope of Market Reports:

Parkinson’s disease is a neurodegenerative disorder in which parts of the brain become progressively damaged over many years. It is a type of movement disorder. It occurs when nerve tissue is unable to produce a chemical named ’Dopamine’ which is used to send signals that help you move your body. Parkinson’s disease is usually developed for aged people i.e. above 60 years, but it can also start earlier. It is more common in men than in women. The cause of Parkinson’s disease is unknown, but researchers think that both genetic and environmental factors are involved. Primary symptoms include tremors, Stiffness, Slowness, impaired balance, mild memory & Thinking problem and shuffling gait. Secondary symptoms include Anxiety, Depression, Fatigue, Low blood pressure, muscle cramp, Speech & communication problem, skin & Dental Problem and Dizziness, and Dementia. Risk of Parkinson’s disease increases with age and the disease mainly affects person over 50 years of age. The development of Parkinson’s disease and the degree of destruction differ from person to person.

Many people with Parkinson’s disease live long productive lives, whereas others become disabled much more quickly. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks. Malnutrition and weight maintenance is common problem for people with Parkinson’s disease. There is no test to diagnose Parkinson’s disease with certainty. Treatment options include medication or surgical treatment. Combination of Levodopa with carbidopa is considered as a gold standard for symptomatic treatment of Parkinson’s disease. Surgical treatment options include deep brain stimulation and Carbidopa/levodopa enteral suspension therapy but surgical therapy is effective only for patients who have previously responded to Levodopa therapy. Commercially available drugs for treatment of Parkinson’s disease are Sinemet, Safinamide, Rotigotine, Ropinirole, Pramiprexol, Amantidine, Cycloset, Parlodel (Bromocriptine Mesylate), Rytary, Azilect, Northera, Stalevo, Comtess/Comtan and others. More than past decade, huge improvement has been made in the treatment of Parkinson’s disease such as identification of new therapeutic targets through genetic research, understanding the common mutations that contribute to Parkinson’s disease etc.

Global Parkinson’s diseases Treatment Market report is segmented on the basis of Medication, Medical devices, End user, Distribution Channels and Geography. Based on Medication Global Parkinson’s disease Treatment Market is classified into Dopamine Precursors, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO (Monoamine Oxidase), Inhibitors and Others (anticholinergics, antihistaminics etc.)

On the basis of Medical Devices Global Parkinson’s disease Treatment Market is classified into Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices and others. On the basis of End User Global Parkinson’s disease Treatment Market is classified into Hospitals, Homecare setting, Clinics and Others. On the basis of Distribution Channel Global Parkinson’s disease Drug Market is classified into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies and Drug Stores.

The regions covered in Global Parkinson’s diseases Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Parkinson’s Disease Treatment Market Key Players

  • Teva Pharmaceuticals
  • AstraZeneca
  • Novartis AG
  • Boehringer Ingelheim
  • GlaxoSmithKline Plc.
  • Salix Pharmaceuticals
  • mpax Laboratories
  • Orion Corporation
  • Mylan N.V.
  • Cipla Inc.
  • Daiichi Sankyo
  • Apotex Inc
  • Impax Laboratories
  • Lundbeck
  • Sun Pharma
  • Wockhardt
  • UCB
  • Valeant Pharmaceuticals Acadia
  • Abbvie
  • Zydus Cadilla
  • Strides
  • 1 A Pharma
  • Upsher-Smith
  • Intas, US World Meds
  • Dr. Reddy’s
    Medtronic plc
  • Biotie Therapies Corp.
  • Adamas Pharmaceuticals Inc.
  • Akorn Inc.
  • Astellas Pharma Inc.
  • Desitin Arzneimittel GmbH
  • Endo International plc
  • Kyowa Hakko Kirin
  • Newron Pharmaceuticals and Merck.

Parkinsons Disease Treatment Market

Parkinson’s Disease Treatment Market Segmentation:

By Medication Analysis -

  • Dopamine Precursor,
  • Peripheral Decarboxylase Inhibitors,
  • COMT (Catechol-O-methyltransferase) Inhibitors,
  • MAO(monoamine oxidase) Inhibitors, 
  • Others (anticholinergics, antihistaminics etc.)

By Medical Devices Analysis -

  • Deep Brain Stimulation (DBS) Devices
  • Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices
  • Others

By End User Analysis -

  • Hospitals
  • Clinics
  • Homecare setting
  • Others

By Distribution Channel -

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Drug Store

Market Dynamics –

Global Parkinson’s disease Treatment Market is mainly driven by the growing prevalence of Parkinson’s disease and government funding for research on Parkinson’s disease. The increase in the number of geriatric population and technological advancements such as combination therapies for prolonged the action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are few other causes that are possible to boost the Parkinson’s disease Treatment market. However some restraints like the availability of alternative treatments is expected to hold back the market and the expiry of patents for several drugs such as Stalevo, Azilect, Rytary, Comtan etc. can cause the termination of the Parkinson’s disease Treatment market. The high cost of treatment such as 14.4 Billion USD and lack of expertise for early diagnosis is likely to restrict the market growth.

Also lack of novel and successful therapies in the market to reduce the risk of mortality restraints for this market. The opportunities for Global Parkinson’s disease Treatment market include upcoming technologies like surface EMG (Electromyography) sensors, Pulse oximetry sensors, development in personalized medicine along with huge investment in anti-Parkinson’s drugs research will boost the global Parkinson’s disease Treatment market. Also development of novel drugs and combination therapy with less side effects and better survival rates is expected to increase the global Parkinson’s disease Treatment market.

Regional Analysis –

Europe is likely to achieve the largest share of the global Parkinson’s disease treatment market, which is expected to be followed by North America with a sizeable market share. High knowledge about the treatment, increase in expenditure for Research & Development, favorable medicinal reimbursement regulations and policies, the high occurrence of Parkinson’s disease, the rapidly growing geriatric population and potential medical pipeline products are likely to contribute to the major share of Europe in Global Parkinson’s disease treatment market.

The global Parkinson’s disease treatment market in the Asia Pacific is anticipated to develop at a profitable rate. The market share of the global Parkinson’s disease treatment market is to be expected to grasp by China and Japan in the Asia Pacific, due to the large population of elderly people who are affected with Parkinson’s disease. Furthermore, an increase in awareness of the disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Drone Logistics and Transportation Market Agriculture Robots and Drone Market Military drone market Commercial Drone Market UAV Drones Market LiDAR Drone Market Disinfection Drone Market Delivery Drones Market Racing Drone Market Underwater Drone Market Small Drone Market Consumer Drone Market Photography Drone Market Utility Drones Market Firefighting Drone Market Artificial Intelligence Manned Drone Market Autonomous BVLOS Drone Market Bubble Drone Market Target Drone Market Maritime Drone Market Spraying Drone Market Thermal Drone Market

Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2028
Market Size in 2021: USD 6352.7 Million 
Base year considered 2020
Forecast Period CAGR %:

6.2% 

Market Size Expected in 2028: USD 9678.9 Million 
Tables, Charts & Figures: 175
Pages 200
Parkinson’s Disease Treatment Companies Teva Pharmaceuticals, AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Salix Pharmaceuticals, mpax Laboratories, Orion Corporation, Mylan N.V., Cipla Inc., Daiichi Sankyo, Apotex Inc, Impax Laboratories,  others
Segments Covered By Medication, By Medical Devices Analysis, By End User, By Distribution Channel 
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global Parkinson’s disease Treatment Market Reports:

  • Global Parkinson’s disease Treatment Market report covers in-depth historical and forecast analysis.
  • Global Parkinson’s disease Treatment Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sales (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
  • Global Parkinson’s disease Treatment Market report helps to identify opportunities in the marketplace.
  • Global Parkinson’s disease Treatment Market report covers extensive analysis of emerging trends and competitive landscape.

On Special Requirement Parkinson’s disease Treatment Market Report is also available for the below Regions and Country:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA


Frequently Asked Questions (FAQ) :
Global Parkinson’s Disease Treatment Market is Anticipated to Reach USD 9678.9 Million by 2028 with a CAGR of 6.2% over the forecast period.
Teva Pharmaceuticals, AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Salix Pharmaceuticals, mpax Laboratories, Orion Corporation, Mylan N.V., Cipla Inc., Daiichi Sankyo, Apotex Inc, Impax Laboratories
Global Parkinson’s Disease Treatment Market is valued at USD 6352.7 Million in 2021
The increase in number of geriatric population and technological advancements such as combination therapies for prolong action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are few other causes which are possible to boost the Parkinson’s disease Treatment market.
Europe is likely to achieve the largest share of the global Parkinson’s disease treatment market,



Interested in this report?

Parkinson’s Disease Treatment Market Share, Size, Trends, Growth And Industry Analysis By 2028

report cover

Parkinson’s Disease Treatment Market Size, Share, Companies & Trends Analysis Report by Medication Analysis ( Dopamine Precursor, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO(monoamine oxidase) Inhibitors, Others (anticholinergics, antihistaminics, etc.)) By Medical Devices Analysis ( Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices, Others), By End User Analysis( Hospitals, Clinics, Homecare setting, Others) Based On Region And Segment Forecasts, 2022 - 2028

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.
Brandessence market research actively tracks, monitors, and analyses key industry trends in real-time via B2B surveys in 60 + countries and territories.

    Pricing


Looking for Regional Reports?